Kala Pharmaceuticals, Inc. (KALA)
USD 3.75
(0.81%)
USD 3.75
(0.81%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -36.08 Million USD | 52.4% |
| 2022 | -36.69 Million USD | 23.75% |
| 2021 | -131.95 Million USD | -11.81% |
| 2020 | -92.9 Million USD | -11.5% |
| 2019 | -83.25 Million USD | -36.22% |
| 2018 | -62.46 Million USD | -60.2% |
| 2017 | -40.54 Million USD | -22.1% |
| 2016 | -32.1 Million USD | -106.36% |
| 2015 | -15.74 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -9.57 Million USD | 21.64% |
| 2024 Q1 | -11.7 Million USD | -45.1% |
| 2023 Q4 | -9.27 Million USD | -5.81% |
| 2023 FY | - USD | 52.4% |
| 2023 Q1 | -11.36 Million USD | -11.75% |
| 2023 Q2 | -8.56 Million USD | 24.64% |
| 2023 Q3 | -8.76 Million USD | -2.31% |
| 2022 Q4 | -10.16 Million USD | 25.79% |
| 2022 FY | - USD | 23.75% |
| 2022 Q2 | -26.6 Million USD | 13.31% |
| 2022 Q3 | -13.7 Million USD | 48.49% |
| 2022 Q1 | -30.68 Million USD | -25.41% |
| 2021 Q1 | -28.02 Million USD | 3.18% |
| 2021 Q3 | -25.79 Million USD | 10.29% |
| 2021 Q4 | -24.46 Million USD | 5.15% |
| 2021 FY | - USD | -11.81% |
| 2021 Q2 | -28.75 Million USD | -2.62% |
| 2020 FY | - USD | -11.5% |
| 2020 Q4 | -28.94 Million USD | -13.18% |
| 2020 Q3 | -25.57 Million USD | -20.74% |
| 2020 Q2 | -21.17 Million USD | -8.07% |
| 2020 Q1 | -19.59 Million USD | 1.09% |
| 2019 Q3 | -20.77 Million USD | 4.57% |
| 2019 Q2 | -21.76 Million USD | 4.07% |
| 2019 Q1 | -22.68 Million USD | 0.18% |
| 2019 FY | - USD | -36.22% |
| 2019 Q4 | -19.81 Million USD | 4.61% |
| 2018 Q2 | -14.02 Million USD | -30.35% |
| 2018 Q3 | -15 Million USD | -7.03% |
| 2018 FY | - USD | -60.2% |
| 2018 Q1 | -10.75 Million USD | 1.22% |
| 2018 Q4 | -22.72 Million USD | -51.47% |
| 2017 Q4 | -10.88 Million USD | -17.5% |
| 2017 Q1 | -9.45 Million USD | 4.01% |
| 2017 Q2 | -9.52 Million USD | -0.7% |
| 2017 Q3 | -9.26 Million USD | 2.68% |
| 2017 FY | - USD | -22.1% |
| 2016 Q4 | -9.85 Million USD | -2.47% |
| 2016 Q2 | -7.76 Million USD | -55.25% |
| 2016 FY | - USD | -106.36% |
| 2016 Q1 | -4.99 Million USD | 0.0% |
| 2016 Q3 | -9.61 Million USD | -23.88% |
| 2015 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Esperion Therapeutics, Inc. | -150.1 Million USD | 75.963% |
| Theratechnologies Inc. | -10.31 Million USD | -249.876% |
| Safety Shot Inc | -12.18 Million USD | -196.114% |
| Cosmos Health Inc. | -17.06 Million USD | -111.478% |
| Cronos Group Inc. | -72.14 Million USD | 49.99% |
| Ironwood Pharmaceuticals, Inc. | -924.86 Million USD | 96.099% |
| Organogenesis Holdings Inc. | 36.03 Million USD | 200.142% |
| Universe Pharmaceuticals INC | -3.21 Million USD | -1022.278% |
| ProPhase Labs, Inc. | -14.82 Million USD | -143.353% |
| Sonoma Pharmaceuticals, Inc. | -4.52 Million USD | -697.392% |
| Dynavax Technologies Corporation | 9.66 Million USD | 473.288% |
| Radius Health, Inc. | 38.31 Million USD | 194.184% |
| China SXT Pharmaceuticals, Inc. | -2.35 Million USD | -1434.745% |
| Alvotech | -484.86 Million USD | 92.558% |
| Sunshine Biopharma, Inc. | -3.82 Million USD | -843.464% |
| Alpha Teknova, Inc. | -25.53 Million USD | -41.282% |
| Intra-Cellular Therapies, Inc. | -158.85 Million USD | 77.286% |
| SCYNEXIS, Inc. | 73.47 Million USD | 149.105% |
| Harrow Health, Inc. | 9.72 Million USD | 471.099% |
| Biofrontera Inc. | -18.45 Million USD | -95.535% |
| DURECT Corporation | -24.68 Million USD | -46.176% |
| Supernus Pharmaceuticals, Inc. | 98.26 Million USD | 136.72% |
| ANI Pharmaceuticals, Inc. | 109.32 Million USD | 133.006% |
| OptiNose, Inc. | -15.55 Million USD | -131.994% |
| RedHill Biopharma Ltd. | 26.26 Million USD | 237.371% |
| Aquestive Therapeutics, Inc. | 1.18 Million USD | 3152.623% |
| Cumberland Pharmaceuticals Inc. | -710.85 Thousand USD | -4975.895% |
| SIGA Technologies, Inc. | 84.15 Million USD | 142.873% |
| Lifecore Biomedical, Inc. | 812 Thousand USD | 4543.596% |
| Shineco, Inc. | -26.55 Million USD | -35.882% |
| Phibro Animal Health Corporation | 84.6 Million USD | 142.647% |
| Procaps Group S.A. | 104.02 Million USD | 134.685% |
| TherapeuticsMD, Inc. | -8.4 Million USD | -329.496% |
| Regencell Bioscience Holdings Limited | -3.61 Million USD | -897.394% |
| Viatris Inc. | 3.51 Billion USD | 101.026% |
| Sunshine Biopharma, Inc. | -3.82 Million USD | -843.464% |
| Rockwell Medical, Inc. | -4.69 Million USD | -668.683% |
| Incannex Healthcare Limited | -18.5 Million USD | -94.996% |
| Aytu BioPharma, Inc. | -1.01 Million USD | -3465.415% |
| Tilray Brands, Inc. | -72.84 Million USD | 50.466% |
| Collegium Pharmaceutical, Inc. | 308.32 Million USD | 111.702% |
| PetIQ, Inc. | 81.48 Million USD | 144.28% |
| Silver Spike Investment Corp. | 7.34 Million USD | 591.573% |
| Neurocrine Biosciences, Inc. | 416.1 Million USD | 108.671% |
| Journey Medical Corporation | 1.92 Million USD | 1978.293% |
| Alimera Sciences, Inc. | 7.27 Million USD | 595.904% |
| Petros Pharmaceuticals, Inc. | -4.21 Million USD | -756.674% |
| Assertio Holdings, Inc. | -222.44 Million USD | 83.78% |
| Shuttle Pharmaceuticals Holdings, Inc. | -3.99 Million USD | -804.164% |
| Embecta Corp. | 245.4 Million USD | 114.703% |
| Cyclo Therapeutics, Inc. | -20.03 Million USD | -80.133% |
| Procaps Group, S.A. | 104.02 Million USD | 134.685% |
| PainReform Ltd. | -9.56 Million USD | -277.072% |
| Avadel Pharmaceuticals plc | -149.12 Million USD | 75.804% |
| Hempacco Co., Inc. | -12.77 Million USD | -182.481% |
| Talphera, Inc. | -9.84 Million USD | -266.612% |
| Pacira BioSciences, Inc. | 162.89 Million USD | 122.15% |
| Alvotech | -484.86 Million USD | 92.558% |
| Lantheus Holdings, Inc. | 491 Million USD | 107.349% |
| Kamada Ltd. | 21.53 Million USD | 267.558% |
| Indivior PLC | 66 Million USD | 154.67% |
| Currenc Group, Inc. | -1.9 Million USD | -1798.479% |
| Evoke Pharma, Inc. | -7.29 Million USD | -394.796% |
| Flora Growth Corp. | -45.87 Million USD | 21.339% |
| Cyclo Therapeutics, Inc. | -20.03 Million USD | -80.133% |
| Evolus, Inc. | -41.81 Million USD | 13.7% |
| HUTCHMED (China) Limited | 25.52 Million USD | 241.343% |
| Amphastar Pharmaceuticals, Inc. | 241.46 Million USD | 114.943% |
| Akanda Corp. | -27.73 Million USD | -30.092% |